Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

被引：0
|
作者：
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
机构：
[1] St. Josef-Hospital/Ruhr-University Bochum,Medical Image Analysis Center
[2] University Hospital Basel,Barts and The London School of Medicine and Dentistry
[3] Queen Mary University of London,Department of Neurology
[4] University of Warmia and Mazury,Department of Neurology, First Faculty of Medicine
[5] Charles University,undefined
[6] Hospital Vall d’Hebron University,undefined
[7] Rush University Medical Center,undefined
[8] DKD Helios Klinik Wiesbaden,undefined
[9] AbbVie Inc.,undefined
[10] Biogen,undefined
[11] Biogen,undefined
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
Daclizumab beta; Relapsing–remitting multiple sclerosis; SELECTED; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2851 / 2864
页数：13
相关论文
共 50 条
  • [21] Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
    Hauser, Stephen L.
    Zielman, Ronald
    Das Gupta, Ayan
    Xi, Jing
    Stoneman, Dee
    Karlsson, Goeril
    Robertson, Derrick
    Cohen, Jeffrey A.
    Kappos, Ludwig
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (11-12) : 1452 - 1464
  • [22] Safety and efficacy with alemtuzumab over 13?years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
    Coles, Alasdair J.
    Achiron, Anat
    Traboulsee, Anthony
    Singer, Barry A.
    Pozzilli, Carlo
    Oreja-Guevara, Celia
    Giovannoni, Gavin
    Comi, Giancarlo
    Freedman, Mark S.
    Ziemssen, Tjalf
    Shiota, Debora
    Rawlings, Andreea M.
    Wong, Alana T.
    Chirieac, Magdalena
    Montalban, Xavier
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [23] Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study
    Chiorean, Michael
    Vermeire, Severine
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Zhang, Jinkun
    Sands, Bruce E.
    Lazin, Krisztina
    Cabell, Chris H.
    Naik, Snehal U.
    Klassen, Preston
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S445 - S446
  • [24] Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
    Vermeire, Severine
    Chiorean, Michael
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Zhang, Jinkun
    Sands, Bruce E.
    Lazin, Krisztina
    Klassen, Preston
    Naik, Snehal U.
    Cabell, Christopher H.
    Sandborn, William J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (06): : 950 - 959
  • [25] Update on Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis: Final Data From an Open-Label Extension Study
    Selmaj, Krzysztof
    Cohen, Jeffrey
    Steinman, Lawrence
    Comi, Giancarlo
    Bar-Or, Amit
    Hartung, Hans-Peter
    Montalban, Xavier
    Kappos, Ludwig
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Krakovich, Anthony
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1017 - 1018
  • [26] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [27] Results of the long-term (eight-year) prospective, open-label trial of glatiramer acetate for relapsing multiple sclerosis
    Johnson, KP
    Brooks, BB
    Ford, CC
    Goodman, AD
    Guarnaccia, JB
    Lisak, RP
    Myers, LW
    Panitch, HS
    Pruitt, AA
    Kachuck, N
    Wolinsky, JS
    NEUROLOGY, 2002, 58 (07) : A458 - A458
  • [28] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Afsari, S.
    Shi, F.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
  • [29] Long-term Efficacy of Ozanimod in Relapsing Multiple Sclerosis in DAYBREAK: An Open-Label Extension of the Phase 3 SUNBEAM and RADIANCE Trials
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-or, A.
    Arnold, D. L.
    Hartung, H-P
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Hetzer, J.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 473 - 474
  • [30] Long-term efficacy and safety of ocrelizumab in treatment-naive patients with early relapsing multiple sclerosis: 7-year data from the OPERA open-label extension trials
    Cerqueira, J.
    Berthele, A.
    Cree, B.
    Filippi, M.
    Pardo, G.
    Pearson, O.
    Trabloulsee, A.
    Ziemssen, T.
    Vollmer, T.
    Bernasconi, C.
    Mandel, C.
    Overell, J.
    Havrdova, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 634 - 635
12345